Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201345 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2THRBALOX15AKT1CA1 | |
| SCHEMBL3470835 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2THRBALOX15 | |
| SCHEMBL12949780 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2THRBALOX15 | |
| SCHEMBL8286845 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2THRBALOX15 | |
| SCHEMBL13776551 | 0.77 | — | — | |
| SCHEMBL11000184 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2THRBALOX15 | |
| SCHEMBL11105614 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2THRBALOX15 | |
| SCHEMBL10110367 | 0.72 | SMN1; SMN2 (0.48) | SMN1; SMN2THRBALOX15AKT1CA1 | |
| SCHEMBL16369092 | 0.72 | SMN1; SMN2 (0.48) | SMN1; SMN2THRBALOX15AKT1CA1 | |
| SCHEMBL12831196 | 0.72 | SMN1; SMN2 (0.43) | SMN1; SMN2THRBALOX15CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | SMN1; SMN2 2804/4885THRB 4008/4885ALOX15 917/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | SMN1; SMN2 2804/4885THRB 4008/4885ALOX15 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.